YS Biopharma Co., Ltd., a China-based global biopharmaceutical company, announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) for the Investigational New Drug Application (IND) for PIKA COVID-19 vaccine.
Presently, the vaccine is in the phase three, multi-country, multi-centre clinical trial carried out in Southeast Asian and Middle East countries. The vaccine includes PIKA adjuvant and a stable trimeric form of the recombinant SARS-CoV-2 spike (S) protein as its main antigen component.
The planned study in the USA is a Phase one, open label, dose-escalation study to assess the safety, tolerability, and immunogenicity of a single booster dose of the vaccine in healthy adults, who have completed a primary COVID-19 vaccine series. It is expected to offer useful information about PIKA COVID-19 vaccine as a heterologous booster against dominant or emerging variants in the USA, such as omicron BA.5 or XBB, regardless of earlier vaccination or infection history.
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Micron Biomedical names new scientific advisor to CEO
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences